Clinical trials
Lung Cancer (Suspected or Confirmed) clinical trials
Below are recruiting lung cancer (suspected or confirmed) clinical trials, each written for real people, not researchers. We’re tracking 6,580 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05887609RecruitingPhase 2
Maintenance treatment for FRalpha-positive ovarian or endometrial cancer
This Phase 2 trial tests a combination of two medicines (mirvetuximab soravtansine and olaparib) as ongoing “maintenance” treatment after your best response to prior platinum chemotherapy. It may help keep cancer from growing longer in certain women whose tumors strongly match a specific marker (FRalpha).
Irvine, CaliforniaAges 18–100 - NCT05872295RecruitingPhase 1
Study drug for HER2-positive advanced cancers
This Phase 1 trial tests IKS014 to see how safe it is and how well it works in advanced solid tumors that have HER2. You may be eligible if your tumor is HER2-positive (including certain “low HER2” types) and your body’s blood counts and organ function are strong enough.
Newport Beach, CaliforniaAges 18 years+ - NCT05873192RecruitingPhase 2
Talazoparib plus enzalutamide before prostate surgery
This trial studies whether taking talazoparib and enzalutamide before surgery can shrink or control prostate cancer. If treatment works, it may make the cancer easier to remove with a radical prostatectomy.
Houston, TexasAges 18 years+ - NCT05827523RecruitingPhase 3
Surgery for ovarian cancer with or without heated chemotherapy
This trial studies whether adding a special heated chemotherapy treatment during surgery (called HIPEC) improves outcomes for some people with ovarian, fallopian tube, or primary peritoneal cancer. It compares surgery alone versus surgery plus HIPEC after you’ve had chemotherapy first.
Sejong, Chungcheongnam-doAges 18–80 - NCT05819892RecruitingPhase 1
Dostarlimab with chemo and radiation for advanced womb cancer
This Phase 1 trial studies how safe and tolerable it is to add dostarlimab (an immunotherapy) to standard chemo and radiation, followed by more chemotherapy, for stage IIIC endometrial cancer that has spread to lymph nodes. It aims to see whether this combination can be given safely soon after surgery.
Houston, TexasAges 18 years+ - NCT05789485RecruitingPhase 2
Exercise program to reduce treatment side effects in GI cancer
This trial studies whether a structured exercise plan can lessen side effects from chemotherapy in people with colorectal or stomach/esophagus solid tumors. If you’re about to start chemotherapy, the study will check whether exercising helps you feel and function better during treatment.
Hartford, ConnecticutAges 18 years+ - NCT05785065RecruitingPhase 2
Mycophenolate for early lung scarring in systemic sclerosis
This Phase 2 study tests whether mycophenolate mofetil (MMF) can slow or improve early, mild lung scarring in people with systemic sclerosis. It’s meant for systemic sclerosis patients who have lung involvement on a CT scan but still have good breathing test results.
Montreal, QuebecAges 18 years+ - NCT05806931RecruitingPhase 2
Alternating two pills plus bevacizumab for advanced colon cancer
This Phase 2 study tests a treatment plan that alternates two cancer pills and adds bevacizumab (a blood-vessel drug) for metastatic colon cancer that has come back or worsened after standard treatment. It may help shrink tumors and slow disease growth after later-line therapy options.
Elizabeth, New JerseyAges 18 years+ - NCT05800574RecruitingPhase 2
Targeted neck radiation for p16-positive favorable throat cancer
This Phase 2 study tests whether a more precisely targeted radiation plan to the neck can work for people with p16-positive oropharynx cancer that is considered “favorable risk.” Doctors use special imaging to map where lymph nodes are likely involved, aiming to treat the right areas while avoiding unnecessary treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05792150Recruiting
Registry for young women with certain early breast cancer treatments
This registry collects information from pre- or perimenopausal women with early breast cancer who are treated with standard care, plus tumor testing like MammaPrint®. It may help doctors better understand which treatments work best for different risk groups.
Baden-Baden, Baden-WurttembergAges 18–60 - NCT05774951RecruitingPhase 3
Camizestrant for hormone-positive, HER2-negative early breast cancer
This trial tests camizestrant, a medicine that blocks estrogen signaling, to help prevent hormone-positive, HER2-negative early breast cancer from coming back. You may be eligible if your cancer has higher- or intermediate-risk features and you already completed at least 2 years of hormone therapy.
Birmingham, AlabamaAges 18–130 - NCT05769010RecruitingPhase 2
HER2-positive or low breast cancer brain metastasis drug study
This Phase 2 study tests SHR-A1811 in people with HER2-positive (or HER2-low) advanced breast cancer that has spread to the brain. It aims to shrink brain tumors and control the cancer in the brain, especially when there was no need for urgent local treatment like radiation or surgery.
Zhengzhou, HenanAges 18–75 - NCT05756569RecruitingPhase 2
Enfortumab plus pembrolizumab for advanced bladder cancer variants
This trial studies enfortumab vedotin plus pembrolizumab (immunotherapy) for people with advanced bladder cancer that has a “variant” or non-urothelial subtype. It aims to shrink tumors and improve outcomes when standard options have not worked or are no longer enough.
Atlanta, GeorgiaAges 18 years+ - NCT05716893RecruitingPhase 2
Aerobic exercise program for people getting breast cancer treatment
This Phase 2 study tests whether a supervised aerobic (cardio) training program can improve health and exercise capacity for people receiving treatment for primary breast cancer. You may join if you currently do very little moderate-to-vigorous exercise and can safely complete a special treadmill test that measures breathing and heart response.
Basking Ridge, New JerseyAges 18 years+ - NCT05741164RecruitingPhase 2
Propranolol plus pembrolizumab for hard-to-treat breast cancer
This Phase 2 trial studies whether adding propranolol to pembrolizumab can “re-sensitize” tumors and slow cancer in triple-negative breast cancer that no longer responds to checkpoint immunotherapy. It may help some people whose cancer has grown despite prior pembrolizumab and chemotherapy.
Atlanta, GeorgiaAges 18 years+ - NCT05732623Recruiting
Study of early colorectal cancer risk factors in younger adults
This study looks at factors that may contribute to early-onset colorectal cancer (cancer in the colon or rectum diagnosed at a young age). It compares people with early-onset colorectal cancer to people without cancer to better understand possible causes and risks.
Denver, ColoradoAges 18–49 - NCT05691465RecruitingPhase 2
Radiation drug for metastatic prostate cancer with neuroendocrine cells
This Phase 2 study tests whether a radioactive medicine called lutetium Lu 177 dotatate is safe and effective for metastatic prostate cancer that has neuroendocrine features. It also checks whether patients’ scans show the cancer absorbs the drug (a requirement to start treatment).
Duarte, CaliforniaAges 18 years+ - NCT05704829RecruitingPhase 2
Trastuzumab-deruxtecan before surgery for HER2-positive early breast cancer
This trial compares giving trastuzumab-deruxtecan before surgery versus standard chemotherapy plus trastuzumab and pertuzumab. It aims to see which approach works better to shrink or control HER2-positive early breast cancer and improve outcomes.
Baden-Baden, Baden-WurttembergAges 18 years+ - NCT05640999RecruitingPhase 2
Trial for early uterine cancer with POLE mutation after surgery
This Phase 2 trial studies an added (adjuvant) treatment for early-stage uterine cancer that has a specific genetic change called POLE mutation and does not have a p53 abnormal pattern. The goal is to lower the risk of the cancer coming back after surgery.
Anchorage, AlaskaAges 18 years+ - NCT05640791RecruitingPhase 2
Durvalumab with chemo before surgery for bile duct cancer
This trial tests giving durvalumab (an immunotherapy drug) together with chemotherapy before surgery for bile duct or gallbladder cancer. The goal is to see if this combination shrinks tumors and improves outcomes for patients whose cancer is considered high-risk but still removable.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT05672524RecruitingPhase 2
Tucatinib plus trastuzumab for HER2-positive rectal cancer
This Phase 2 study tests whether tucatinib combined with trastuzumab can slow or shrink rectal cancer that is HER2-positive and has certain genetic tumor features. If you qualify, you may benefit from a targeted treatment approach aimed at the HER2 pathway.
Basking Ridge, New JerseyAges 18 years+ - NCT05652348Recruiting
Predicting outcomes after heated chemotherapy for stomach or colon spread
This study tries to better predict how well patients do after heated chemotherapy placed in the abdomen during surgery for stomach or colon cancer that has spread to the lining of the abdomen. It may help doctors choose the best treatment plan and timing for future patients.
BerlinAges 18 years+ - NCT05656235RecruitingPhase 2
Study of keeping kidneys longer in upper tract bladder cancer
This Phase 2 trial studies whether a combination treatment can control high-grade upper tract urothelial cancer without removing the kidney and ureter (radical nephroureterectomy). It may help people who must avoid surgery or choose not to have it because of medical risk.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05601440RecruitingPhase 2
Trial for metastatic breast cancer that resisted CDK4/6 treatment
This Phase 2 study tests treatments guided by blood testing (“liquid biopsy”) in people with hormone receptor–positive, HER2-negative metastatic breast cancer that has progressed after standard CDK4/6 medicine plus hormone therapy. It aims to find a better way to control cancer after the first treatment stops working.
Calgary, AlbertaAges Any age
Hear when a new Lung Cancer (Suspected or Confirmed) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (suspected or confirmed)?
- Yes. Clin2 currently lists 6,580 recruiting lung cancer (suspected or confirmed) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (suspected or confirmed) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (suspected or confirmed) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.